Pharma Pulse 5/24/24: Pre-Approval Information Exchange to Accelerate Product Success, Walgreens Boots Alliance Sells Shares of Cencora & more

Leveraging Pre-Approval Information Exchange to Accelerate Product Success, Patient Access

Alvana Maliqi, Cencora’s associate director of value and access strategy for its commercialization strategy & access solutions division discusses the current state of pre-approval information exchanges.

New Biosimilars Continue to be Approved But Uptake Varies by Class

A recent IQVIA report found that uptake of biosimilars on the market for at least three years varies from 8% for insulin lispro to 82% for bevacizumab.

Despite Setback, Neuralink’s First Brain-Implant Patient Stays Upbeat

Elon Musk’s first human experiment with a computerized brain device developed significant flaws, but the subject, who is paralyzed, has few regrets.

Walgreens Boots Alliance Sells Shares of Cencora for $400 Million of Proceeds

Walgreens Boots Alliance, Inc. announced that it has sold shares of Cencora, Inc. pursuant to a share repurchase by Cencora in the amount of approximately $400 million. With the transaction, Walgreens Boots Alliance’s ownership of Cencora’s common stock has decreased from approximately 13% to approximately 12%.

HDA - Healthcare Distribution Alliance on LinkedIn:

Hear HDA’s Chip Davis discuss the important role of healthcare distributors, and how our organization and members partner with public and private sector partners to support and enhance the resilience of the Rx supply chain:

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs